Detail akcie Aslan Pharma Sp ADR online

Business Summary: ASLAN Pharmaceuticals Limited is a clinical-stage immunology focused biopharmaceutical company. The Company's portfolio is led by eblasakimab (ASLAN004), a potential human monoclonal antibody that binds to the IL-13 receptor a1 subunit (IL-13Ra1), blocking signaling of two pro-inflammatory cytokines, IL-4 and IL-13, which are central to triggering symptoms of atopic dermatitis, such as redness and itching of the skin. It is conducting a Phase II b clinical trial investigating eblasakimab as a therapeutic antibody for moderate-to-severe atopic dermatitis (AD). The Company is also developing farudodstat (ASLAN003), an orally active, potent inhibitor of human dihydroorotate dehydrogenase (DHODH) that has the potential to be a therapy for autoimmune disease. The Company is also focused on developing antagonists of the aryl hydrocarbon receptor (AhR), an immune checkpoint inhibitor, through a joint venture.
Financial Summary: BRIEF: For the nine months ended 30 September 2023, Aslan Pharmaceuticals Ltd (ADR) revenues increased from $0K to $12M. Net loss decreased 17% to $30.7M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Lower net loss reflects Development of New Antitumor Drugs segment loss decrease of 15% to $20.5M. Basic Earnings per Share excluding Extraordinary Items increased from -$4.23 to -$0.63.